Romidepsin (FK228, Depsipeptide)

Name: Romidepsin (FK228, Depsipeptide)
Brand: Selleck Chemicals
SKU: S3020
Rating: 5 (156 reviews)

For research use only.

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

156 publications

Romidepsin (FK228, Depsipeptide) Chemical Structure

CAS No. 128517-07-7

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Selleck's Romidepsin (FK228, Depsipeptide) has been cited by 156 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(4):2390-2399

PubMed: 33544854 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Autophagy, 2021, 1-15

PubMed: 34034634 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1376

PubMed: 33803654 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )

Dev Dyn, 2021, 10.1002/dvdy.294

PubMed: 33410213 ( click the link to review the publication )

Anal Biochem, 2021, 628:114286

PubMed: 34119487 ( click the link to review the publication )

SLAS Discov, 2021, 2472555220983810

PubMed: 33427012 ( click the link to review the publication )

Int J Radiat Biol, 2021, 1-15

PubMed: 33979259 ( click the link to review the publication )

Transl Psychiatry, 2021, 11(1):99

PubMed: 33542189 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

Eur J Immunol, 2021, 10.1002/eji.202048892

PubMed: 33555624 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Clin Epigenetics, 2021, 13(1):41

PubMed: 33632300 ( click the link to review the publication )

J Dermatol Sci, 2021, S0923-1811(21)00005-0

PubMed: 33531202 ( click the link to review the publication )

Life Sci, 2021, 271:119127

PubMed: 33515561 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33046

PubMed: 32599665 ( click the link to review the publication )
PLoS Pathog, 2020, 16(2):e1008151

PubMed: 32109259 ( click the link to review the publication )

Cells, 2020, 10;9(6):E1447

PubMed: 32532133 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

J Virol, 2020, 16;94(9) pii: e01845-19

PubMed: 32051267 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

HIV Med, 2020, 21(11):747-757

PubMed: 33369029 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 10.1007/s00262-020-02653-1

PubMed: 32632663 ( click the link to review the publication )

Oncotarget, 2020, 11(37):3432-3442

PubMed: 32973968 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3589

PubMed: 33266275 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Front Immunol, 2020, 11:1746

PubMed: 33013828 ( click the link to review the publication )

Med Sci Monit, 2020, 26:e918528

PubMed: 31954012 ( click the link to review the publication )

PeerJ, 2020, 8:e10321

PubMed: 33282555 ( click the link to review the publication )

Epigenetics, 2020, 15(4):369-385

PubMed: 31533525 ( click the link to review the publication )

J Clin Invest, 2020, 135711

PubMed: 33270606 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(3):513-526

PubMed: 30521971 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 30979734 ( click the link to review the publication )
Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2152

PubMed: 31772119 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):30

PubMed: 30885250 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1871

PubMed: 31769432 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Mol Neurobiol, 2019, 10.1007/s12035-019-1565-7

PubMed: 30963442 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Pharmacol Res, 2019, 142:192-204

PubMed: 30807866 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(14):5576-5589

PubMed: 30745362 ( click the link to review the publication )

Exp Cell Res, 2019, 375(2):106-112

PubMed: 30579954 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):79

PubMed: 30651077 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(2):278-283

PubMed: 30686534 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )
Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

American Association for Cancer Research, 2019, 10.1158/1078-0432.CCR-18-3989

PubMed: None ( click the link to review the publication )

Oncotarget, 2019, 10(55):5671-5679

PubMed: 31620242 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Blood, 2018, 131(4):397-407

PubMed: 29141948 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4413-4428

PubMed: 30148456 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2024

PubMed: 29789628 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

MBio, 2018, 9(6)

PubMed: 30425153 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Cell Prolif, 2018, 51(3):e12447

PubMed: 29484736 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1400

PubMed: 29362442 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2379546

PubMed: 29731773 ( click the link to review the publication )

Stem Cells Dev, 2018, 27(17):1215-1225

PubMed: 30032710 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)E505

PubMed: 30544928 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Genome Res, 2018, 10.1101/gr.227272.117

PubMed: 29429976 ( click the link to review the publication )

Nat Neurosci, 2018, 21(4):564-575

PubMed: 29531362 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )
Nat Commun, 2017, 8(1):403

PubMed: 28864822 ( click the link to review the publication )

Nat Commun, 2017, 8(1):939

PubMed: 29038521 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1770-1783

PubMed: 28982760 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(7):604-616

PubMed: 28615266 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

Biochem Pharmacol, 2017, 127:90-100

PubMed: 28012958 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(4):551-560

PubMed: 28112184 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6319-6329

PubMed: 28030834 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(30-:48737-48754

PubMed: 28467787 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(16):4119-32

PubMed: 26964571 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

EBioMedicine, 2016, 8:217-229

PubMed: 27428432 ( click the link to review the publication )

PLoS Pathog, 2016, 12(4):e1005545

PubMed: 27082643 ( click the link to review the publication )
J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1875-85

PubMed: 27509880 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(1):71-75

PubMed: 27091426 ( click the link to review the publication )

Leuk Res, 2016, 47:100-8

PubMed: 27294334 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.8379

PubMed: 27028869 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4454-67

PubMed: 26683357 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1561

PubMed: ( click the link to review the publication )

Leukemia, 2015, 29(3):556-66

PubMed: 25118879 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e357

PubMed: 26473529 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )
PLoS One, 2015, 10(12):e0145994

PubMed: 26717578 ( click the link to review the publication )

Tumour Biol, 2015, 36(7):5485-95

PubMed: 26036758 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

J Chem Inf Model, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

J Neurosci, 2013, 33(17):7535-47

PubMed: 23616558 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(8):1591-604

PubMed: 23536727 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Features

More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

Targets

HDAC1 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)
36 nM	47 nM

In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. ^[1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. ^[2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. ^[3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. ^[5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. ^[6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. ^[7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. ^[9]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SU-DHL4	NXvvfpc6S2WubDDWbYFjcWyrdImgRZN{[Xl?	MVqyMlUuOTVibl2=	NHqwWG04OiCq		MmLPbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>?	NYq5fnJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVA6ODdpPkK1O\|kxQTB5PD;hQi=>
U2932	MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MonBNk42NTF3IH7N	MYK3NkBp		MUPpcoR2[2W\|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh	M1TpclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{mwPVA4Lz5{NUe5NFkxPzxxYU6=
OCI-LY7	MorSR4VtdCCYaXHibYxqfHliQYPzZZk>	M1HNeFIvPS1zNTDuUS=>	M4TMZlczKGh?		NVTGSXk6cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	NEXqZY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NFkxPyd-MkW3PVA6ODd:L3G+
Farage	MljJR4VtdCCYaXHibYxqfHliQYPzZZk>	NWDQTo42Oi53LUG1JI5O	NGe4ZXY4OiCq		M2XYTIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	NGLwPIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NFkxPyd-MkW3PVA6ODd:L3G+
LY7/EBV	NXrnToo6S2WubDDWbYFjcWyrdImgRZN{[Xl?	Mkj0Nk42NTF3IH7N	NE[z[WU4OiCq		NW[2N2RXcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	MnX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUC5NFcoRjJ3N{mwPVA4RC:jPh?=
U2932/EBV	NXqwUItCS2WubDDWbYFjcWyrdImgRZN{[Xl?	NEnh[GEzNjVvMUWgcm0>	MkTKO\|IhcA>?		NVjvcYhVcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	NEf2RnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NFkxPyd-MkW3PVA6ODd:L3G+
HCT116	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13RTlUuPTByMDDuUS=>	MU[yOEBp	MmL1SG1UVw>?	NXTt[JNLcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NGO4cpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NlUyPSd-MkW0PVI2OTV:L3G+
ACH-2	NIPLeZBHfW6ldHnvckBCe3OjeR?=	NVX4foxXOS17IH7N	NYnRfHFQOjRiaB?=		Mme4bY5lfWOnczDITXYuOSCHbo[g[ZhxemW\|c3nvci=>	NVHnOIhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFk1PjdpPkK1NVQ6PDZ5PD;hQi=>
MCF-10A	NYfoXIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTZTmpKSzVyPUCuNVfDuTBwMEGgcm0>	NEPDXZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
MCF-7	M37Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LWOGlEPTB;MT6xNOKyOC5{MDDuUS=>	NFTnSW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
SK-BR-3	M2q3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3SyPGlEPTB;MT6wNOKyOC5\|NTDuUS=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
MDA-MB-231	NYLjUXN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzxN3NkUUN3ME2wMlY5yrFyLkG0JI5O	M4\DeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
PC3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHJVVJKSzVyPUGuOlXDuTBwM{Wgcm0>	NYTEc2NZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVQ5PTZpPkK0PVU1QDV4PD;hQi=>
HCT116	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3aTWZKSzVyPUGuNFDDuTBwMECgcm0>	M3;BNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
HCT116-p21-/-	NE\uUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzOfXJjUUN3ME2xMlI3yrFyLkO3JI5O	M2m2e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
S1	NE\mbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTjTWM2OD15Lk[3xtExNjJ7IH7N	MkHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
SW620	M3nBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTBwOURCtVAvOjlibl2=	MkDmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
LOX-IMVI	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwOEhCtVAvODNibl2=	MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
UACC-62	M1vTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7qTWM2OD1yLkW2xtExNjF4IH7N	MnLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
MDA-MB-435	MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrXS25DUUN3ME2wMlkxyrFyLkC2JI5O	MkLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
SF-295	NVTFWGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\HTWM2OD1yLki4xtExNjF3IH7N	NGG1bYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
A549	MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTFwMkdCtVAvOjRibl2=	NXTuSWJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVQ5PTZpPkK0PVU1QDV4PD;hQi=>
H460	NV;GcnJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XHbmlEPTB;Mj61POKyOC56MDDuUS=>	NYXMW\|RvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVQ5PTZpPkK0PVU1QDV4PD;hQi=>
EKVX	NHLpVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXKTWM2OD1zLkOzxtExNjN2IH7N	MlS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
H146	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWD3VW1xUUN3ME2wMlIzyrFyLkC3JI5O	NHvnXnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
H526	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXL0R2pXUUN3ME2wMlE2yrFyLkCzJI5O	NEf3cVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
HuT-78	NVvGOIlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HhO2lEPTB;MT63N:KyOC52NDDuUS=>	Ml\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
HA	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\UcVAvPjJ3LUGwcm0>	MYW0PEBp		NF6yc3dqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>?	NFHMbFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3NVUyOCd-MkS3O\|E2OTB:L3G+
MS-275	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYW1XXNlOC54MkWtNVBvVQ>?	MofZOFghcA>?		MXjpcoR2[2W\|IHGgd4lodmmoaXPhcpRtgSC\|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=>	NHK0cYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3NVUyOCd-MkS3O\|E2OTB:L3G+
CD4 T	NX7RSmdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYO0PEBp		Mmn3SWM2OD12LkZCtVEvOCCwTR?=	NUDlNo82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlI1PTRpPkK0O\|IzPDV2PD;hQi=>
CD4 T	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF\wRmE1QCCq		NW\HPZVNS0N3ME2xNFfDuTF{NjDuUS=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MkS1OEc,OjR5MkK0OVQ9N2F-
CD4+ T	NXuxTlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPT[FZvTUN3ME2zJI5O	M1LRcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1NVA2Lz5{NES5OVExPTxxYU6=
A549	M2XUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfQUYJ{OTEkgKOxNFDDqG6P	NGPIS2ozPC9\|Nj:0PEBp		M{PXNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NG\oN2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4OVc6QSd-MkS0PFU4QTl:L3G+
JJN3	NFXLVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHzwWZkzPC92ODDo		NXWzSJliTUN3MEyx5qCKdk19IES45qCKcA>?	NXXJVXpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwN\|AyPTBpPkK0NFMxOTVyPD;hQi=>
OPM-2	M1zYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlnYNlQwPDhiaB?=		MkX0SWM2OHN;MfMAjY5OQyB2OPMAjYg>	NFvz[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzNFE2OCd-MkSwN\|AyPTB:L3G+
RPMI-8226	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1;PO\|I1NzR6IHi=		MV3FR\|Uxez1zLklihKlvVTtiNElihKlp	MlPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyM{CxOVAoRjJ2MEOwNVUxRC:jPh?=
U266	NUDafop2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHrHZlAzPC92ODDo		NEHnWGFGSzVyc{2xNQKBkW6POzC0PQKBkWh?	Mnv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyM{CxOVAoRjJ2MEOwNVUxRC:jPh?=
CA46	NXLxTYZkSXCxcITvd4l{KEG\|c3H5		MV:2JIg>		M1\oZYlv\HWlZYOgZox2dnRiYYDvdJRwe2m\|	NEf5bFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlE3PCd-MkO5OlYyPjR:L3G+
DG75	NXvqWppRSXCxcITvd4l{KEG\|c3H5		MlW0OkBp		NFnGbVBqdmS3Y3XzJI5wKGGyb4D0c5Nqew>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4NkG2OEc,OjN7Nk[xOlQ9N2F-
Ramos	NF[4T\|FCeG:ydH;zbZMhSXO\|YYm=		MX:2JIg>		M37nRYlv\HWlZYOg[Zh1\W6\|aY\lJIFxd3C2b4Ppdy=>	M2HTRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2NVY1Lz5{M{m2OlE3PDxxYU6=
ST486	MmfrRZBweHSxc3nzJGF{e2G7		MoPHOkBp		MlTSbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4NkG2OEc,OjN7Nk[xOlQ9N2F-
HuT78	MYnBdI9xfG:\|aYOgRZN{[Xl?	NGLXWWgyNzFyL{GwNEBvVQ>?	M33vZ\|Q5KGh?		NWG5eIRKcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=>	M1zvSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOyO\|MzLz5{M{WzNlc{OjxxYU6=
DpVp35	NXqz[2o4SXCxcITvd4l{KEG\|c3H5	NILU[4oyNzFyL{GwNEBvVQ>?	NYS4SlFiPDhiaB?=		M3:3W4lv\HWlZYOgZox2dnRiYYDvdJRwe2m\|	NIPFfZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNlc{Oid-MkO1N\|I4OzJ:L3G+
DpVp50	MmS3RZBweHSxc3nzJGF{e2G7	MXixM\|ExNzFyMDDuUS=>	MkfROFghcA>?		NV75cml1cW6mdXPld{BjdHWwdDDhdI9xfG:\|aYO=	NHy2fXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNlc{Oid-MkO1N\|I4OzJ:L3G+
DpP75	NYCy[3hTSXCxcITvd4l{KEG\|c3H5	MlfqNU8yOC9zMECgcm0>	NYTKUJY4PDhiaB?=		NELlRmRqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MkezNkc,OjN3M{K3N\|I9N2F-
SKOV-3	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDJNgKBmzJybl2=	NHXKO3c4OiCq	MXTEUXNQ	NVvtelY{emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5?	NITFZpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNFM1QCd-MkOwNVA{PDh:L3G+
Brca1 WT	NEOxSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLlN3Yy6oDVMkDuUS=>	NVe5N\|dpPzJiaB?=	MoLXSG1UVw>?	NI\kbVJz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>?	NW\Dd3VxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVA{PDhpPkKzNFExOzR6PD;hQi=>
Brca1 Null	NXTiXoZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jwUlHjiJN{MH7N	NYfqUVBxPzJiaB?=	MUjEUXNQ	MYDy[YR2[2W\|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=>	NXLrW5JrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVA{PDhpPkKzNFExOzR6PD;hQi=>
OVCAR-8	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jG[\|HjiJN{MH7N	MWe3NkBp	MnrHSG1UVw>?	M4PQdJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m\|cHzheIlv	NGLkeHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNFM1QCd-MkOwNVA{PDh:L3G+
NCI/ADR-RES	M4Lq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHENgKBmzJybl2=	MUm3NkBp	MVHEUXNQ	MYLy[YR2[2W\|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=>	NXG1Z4NbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVA{PDhpPkKzNFExOzR6PD;hQi=>
HCT116	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXy5cHVYPSCwTT21NEDPxE1?	M4\rNlI1KGh?	M2m2fWROW09?	M2nrTolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NXr1WJB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlQ6PThpPkKyPVI1QTV6PD;hQi=>
RKO	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUC1JI5ONTVyIN88US=>	M{\xc\|I1KGh?	MoTLSG1UVw>?	NIPTUIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	NE\Qblg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyOFk2QCd-MkK5NlQ6PTh:L3G+
CO115	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVS1JI5ONTVyIN88US=>	MUiyOEBp	NGWzRXVFVVOR	M3\MdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NYD1UVlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlQ6PThpPkKyPVI1QTV6PD;hQi=>
HFS	M3\SPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHBR5pOPSCwTR?=	NHKwem4zPC92OD:3NkBp		MlzHbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=>	NGLRWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGwOlI5Oid-MkKxNFYzQDJ:L3G+
LNCaP	NVLsNGRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED4VnM2KG6P	MXWyOE81QC95MjDo		MmHZbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFyNkK4Nkc,OjJzME[yPFI9N2F-
A549	NVHBWnE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLke2FkPSCwTR?=	MlHyNlQwPDhxN{KgbC=>		MW\pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5	MoO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzME[yPFIoRjJ{MUC2NlgzRC:jPh?=
697	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DTfGlEPTEkgJm95qCKOi53wrDuUS=>	Mo\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3M{iyNVYoRjJzNUO4NlE3RC:jPh?=
697-R	M1zVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojDTWM2OOLCiU5ihKk5NjcEoH7NxsA>	NUG5VFdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1N\|gzOTZpPkKxOVM5OjF4PD;hQi=>
HUT78	NUW1eWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnK2TWM2OD1zIH7N	NFK5UmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG5PFU1PSd-MkGxPVg2PDV:L3G+
THJ-16T	NVr3OHd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHWxNm4yKG6P	MlXGNlQhcA>?		M4rRWYlvcGmkaYTzJINmdGxiZ4Lve5Rp	MmT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6MUC1OlgoRjJyOEGwOVY5RC:jPh?=
HCT116	NUTrVYw3TnWwY4Tpc44hSXO\|YYm=	NHTUSZIzOCCwTR?=	M1H1[lghcA>?		Ml;QcY9lfWyjdHXzJJRz[W6\|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODd\|OUS1OEc,OjB5M{m0OVQ9N2F-
B104	NYLsWJR2TnWwY4Tpc44hSXO\|YYm=	NV3oclhZOiCwTR?=	NX6xNmt[OjRxNEivO\|IhcA>?		NXrLbWxpcW6lcnXhd4V{KHSqZTDzeZJn[WOnIHX4dJJme3Orb36gc4YhS0R{MNMg	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NkWwOUc,OjB4OE[1NFU9N2F-
HL-60	NV7TeoNMS3m2b4TvfIlkcXS7IFHzd4F6	MmL3NU02ODBibl2=	MWGyOEBp		M375UYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{NEG2N{c,OjB4MkSxOlM9N2F-
HP100	MonYR5l1d3SxeHnjbZR6KEG\|c3H5	NYrON\|A1OS13MECgcm0>	MYqyOEBp		Ml7KbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>?	MoP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MkSxOlMoRjJyNkK0NVY{RC:jPh?=
HL-60	Mk\QSpVv[3Srb36gRZN{[Xl?	NED6blkyOCCwTR?=	Ml7tOE83NzF4IHi=		NVzuSItpcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo	Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MkSxOlMoRjJyNkK0NVY{RC:jPh?=
HP100	NIjLXGZHfW6ldHnvckBCe3OjeR?=	MmK5NVAhdk1?	M2DtSVQwPi9zNjDo		M37zeolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?=	MkfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MkSxOlMoRjJyNkK0NVY{RC:jPh?=
HL-60	MYnGeY5kfGmxbjDBd5NigQ>?	M1fwd\|ExNTVyMDDuUS=>	NGTyOJg1KGh?		NEfBWG5l\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC=	NIGzWZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yOFE3Oyd-MkC2NlQyPjN:L3G+
HP100	NILr[XFHfW6ldHnvckBCe3OjeR?=	MmXwNVAuPTByIH7N	MWS0JIg>		NH35cpRl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{NEG2N{c,OjB4MkSxOlM9N2F-
11z	MXjLbY5ie2ViQYPzZZk>	MVOzMVExOCCwTR?=			NYnocoJEemWmdXPld{BJTEGFIHXufplu[XSrYzDhZ5Rqfmm2eTCoTWM2OMLiPTC2MlUhyrFiMD62JI5ud2xxTDm=	MmPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MEWxOFQoRjJyNkC1NVQ1RC:jPh?=
SKOV-3	NWLyOZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHznZWk1NzhxMU[gcm0>	M2XHRlQ5KGh?		MkfibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEW2OEc,OjB2MES1OlQ9N2F-
OVCAR-3	M3[5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:z[IVPPC96L{G2JI5O	M4DlRVQ5KGh?		NHHjNo5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	M2TJdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC0OVY1Lz5{MESwOFU3PDxxYU6=
HBL-2	M{TXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWiyMVExKG6P	NH;Yb5kzPCCq		M4fiU2lEPTB;ND6zJI5O	NGHWT489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC2PFA5OCd-MkCwOlgxQDB:L3G+
Jeko-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2yMVUxKG6P	MnTBNlQhcA>?		Mk\tTWM2OD1zMTDuUS=>	NGnt[oI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC2PFA5OCd-MkCwOlgxQDB:L3G+
Granta-519	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfoT2o4PS12MDDuUS=>	Ml\QNlQhcA>?		M1S0emlEPTB;NUiuOUBvVQ>?	NFv2T\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC2PFA5OCd-MkCwOlgxQDB:L3G+
L1236	NGT0b5FEgXSxdH;4bYNqfHliQYPzZZk>	NHL6XlMyKG6PLUGwNEDPxE1?	MYC0PEBp		Mmn4SWM2OD1yLkC3JO69VQ>?	NGXa[lM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzN\|Q4OCd-MUmyN\|M1PzB:L3G+
L428	MU\DfZRwfG:6aXPpeJkhSXO\|YYm=	MXixJI5ONTFyMDFOwG0>	MnO1OFghcA>?		MXHFR\|UxRTBwNEOg{txO	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ\|M{S3NEc,OTl{M{O0O\|A9N2F-
KM-H2	MkPkR5l1d3SxeHnjbZR6KEG\|c3H5	NEPNWWgyKG6PLUGwNEDPxE1?	NYDBPHUxPDhiaB?=		M3fabGVEPTB;MD61PEDPxE1?	NVezbpdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN\|M1PzBpPkG5NlM{PDdyPD;hQi=>
L540Cy	MYrDfZRwfG:6aXPpeJkhSXO\|YYm=	M{fleVEhdk1vMUCwJO69VQ>?	M4nVcFQ5KGh?		MWfFR\|UxRTBwMU[g{txO	NYPHW3FiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN\|M1PzBpPkG5NlM{PDdyPD;hQi=>
G401	MmK4SpVv[3Srb36gRZN{[Xl?	MWmxNEBvVQ>?	NIe4SVMzPC92OD:3NkBp	NUXHSnV1TE2VTx?=	NF;aSm1qdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44>	NGLsVlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVU5Pid-MUmyNlE2QDZ:L3G+
STM91-01	M{XRXmZ2dmO2aX;uJGF{e2G7	NUHydGVCOTBibl2=	NE\DXlAzPC92OD:3NkBp	MoHPSG1UVw>?	Mn34bY5kemWjc3XzJGNFU05zQzDlfJBz\XO\|aX;u	NHi5Tmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVU5Pid-MUmyNlE2QDZ:L3G+
SJSC	NVTmdmdoTnWwY4Tpc44hSXO\|YYm=	M4TLSlExKG6P	NIrpUGozPC92OD:3NkBp	NWfLeW9{TE2VTx?=	MX\pcoNz\WG\|ZYOgR2RMVjGFIHX4dJJme3Orb36=	MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkG1PFYoRjF7MkKxOVg3RC:jPh?=
BT16	MnnRSpVv[3Srb36gRZN{[Xl?	NEW2VGkyOCCwTR?=	MYSyOE81QC95MjDo	MWjEUXNQ	NULIN2FOcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v	NYrKWpFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlE2QDZpPkG5NlIyPTh4PD;hQi=>
NCI-H1299	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTRwNtMxNE4zKG6pL33s	M2iwc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUe5PFkxLz5zOUG3PVg6ODxxYU6=
NCI-2882	M1ruUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;qfWtKSzVyPUGuOuKyOC5yNDDu[{9udA>?	MoHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzN{m4PVAoRjF7MUe5PFkxRC:jPh?=
HCC95	NFTBOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTJwNdMxNE4xPSCwZz;tcC=>	NWm2OHA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxO\|k5QTBpPkG5NVc6QDlyPD;hQi=>
NCI-H23	NHHwUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJwOdMxNE4zKG6pL33s	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
NCI-H157	NI[5U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LRNGlEPTB;MT62xtExNjB{IH7nM41t	M{f5U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUe5PFkxLz5zOUG3PVg6ODxxYU6=
NCI-H460	NX;3Z3ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTJwMdMxNE4xPyCwZz;tcC=>	M{DIcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUe5PFkxLz5zOUG3PVg6ODxxYU6=
NCI-H1975	NVnuSIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn2cYZlUUN3ME2xMlPDuTBwMESgcocwdWx?	NFnmWYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG3PVg6OCd-MUmxO\|k5QTB:L3G+
NCI-H820	M1rxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XYTWlEPTB;Mj60xtExNjFibnevcYw>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
NCI-H1650	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHL6RXRKSzVyPUSuPeKyOC5\|IH7nM41t	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
DTC1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPzSY55UUN3ME2wMlUyKG6P	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
KAO	NEHtUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG1TWM2OD1yLkmxJI5O	MoLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
SU-CCS-1	M4D5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwOEmgcm0>	M1HKflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
SYO-1	M2nXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDYTm1sUUN3ME2wMlY4KG6P	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
FUJI	NHv5dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nFfWlEPTB;MT6zNUBvVQ>?	NX\ueW4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
SKNMC	M1;TZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ruU2lEPTB;MT6xO{BvVQ>?	M17QV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
402-91	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzqTWM2OD1zLkK2JI5O	M3jFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
1765-92	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnQXYJKSzVyPUGuO\|chdk1?	Mn\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
JN-DSRCT-1	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFz5bphKSzVyPUGuNlUhdk1?	NV;LbW1xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
NMS-2PC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrTN29KSzVyPUCuPFEhdk1?	NGHYVG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
HL60	NFHwSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGryWW1KSzVyPUGuPFYhdk1?	MoizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
A549	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH:1SpJKSzVyPUOuNlQhdk1?	NH62eoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
SW480	NESyUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTJwNkmgcm0>	MoLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
MCF7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDITWM2OD1\|LkW1JI5O	Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
PC-3	NUDHVGpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPZd5ZKSzVyPUKuOVEhdk1?	NGD4eIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
MMRU	M2W1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvvTWM2OD1{LkW3JI5O	NYTlZWtSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
Hs68	NYPsOFBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjoNWVKSzVyPU6xNEBvVQ>?	NXjYZmM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
hMSC-001F	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPUTWM2OD1-MUCgcm0>	NWLDboNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
mammalian cells	MkW1SpVv[3Srb36gZZN{[Xl?				MXLJcohq[mm2aX;uJI9nKEirc4TvcoUh\GWjY3X0fYxie2ViNDDpckBu[W2vYXzpZY4h[2WubIOsJGlEPTBiPTCwMlUyKM7:TT6=	MnnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OES5N\|IoRjF2NUi0PVMzRC:jPh?=
mammalian cells	NUjPeYRLTnWwY4Tpc44h[XO\|YYm=				NIDJVFNKdmirYnn0bY9vKG:oIFjpd5RwdmViZHXhZ4V1gWyjc3WgNUBqdmS3Y3XkJIFk\XS7bHH0[YQhcGm\|dH;u[UBqdiCvYX3tZYxq[W5iY3XscJMvNCCHQ{WwJF0hOzZizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV6NEmzNkc,OTR3OES5N\|I9N2F-
MCF7	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MkTNS5Jwf3SqIHnubIljcXSrb36gc4YhVUOINzDj[YxteyxiSVO1NEA:KDBwMECwO\|Uh\|ryPLh?=	M4\W[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUW4N\|QzLz5zN{m1PFM1OjxxYU6=
A498	NIjrbFVEgXSxdH;4bYNqfHliYYPzZZk>		NGfLblU3KGSjeYO=		MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJHRIUSB;IECuNFI5KM7:TT6=	Mn;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
COLO205	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=		M2DPclYh\GG7cx?=		MnPqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR29NVzJyNTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCWR1mgQUAxNjB\|MTFOwG0v	M{DGU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
U251	M2fjc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3zBdlYh\GG7cx?=		NFnzVpVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvODNzIN88UU4>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
RXF393	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		NEXRTXk3KGSjeYO=		NFTEfm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTYEZ\|OUOgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiVFfJJF0hOC5yNkKg{txONg>?	MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
MDA-MB-468	NIPCRYFEgXSxdH;4bYNqfHliYYPzZZk>		MoXxOkBl[Xm\|		NX\zcHp5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBVT0liPTCwMlA6KM7:TT6=	M4XJeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
COLO205	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=		MYS2JIRigXN?		MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUAxNjB7MjFOwG0v	NYfPOpluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
UACC257	MnrBR5l1d3SxeHnjbZR6KGG\|c3H5		NVztSHl7PiCmYYnz		MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVRWNEOjV5IHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvODl3IN88UU4>	M2TscVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
U251	NFv5OJBEgXSxdH;4bYNqfHliYYPzZZk>		NWLZTJZ1PiCmYYnz		NHXXb21EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUAxNjF\|IN88UU4>	M2HTdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
A498	Ml6zR5l1d3SxeHnjbZR6KGG\|c3H5		M{e0d\|Yh\GG7cx?=		NXfzXnhYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR7ODDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hOC5{IN88UU4>	NHG2Smo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
NCI-H322M	NVf2U3lVS3m2b4TvfIlkcXS7IHHzd4F6		NV3Tc3N4PiCmYYnz		M4DFcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KM{KyUUBk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDUS2khRSByLkKzJO69VS5?	M3\qfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
SF295	M3TNcGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUDZ[Vg5PiCmYYnz		NUe0T5ZoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{OUWgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiVFfJJF0hOC5{NTFOwG0v	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
RXF393	NVLCPHZ1S3m2b4TvfIlkcXS7IHHzd4F6		MlvUOkBl[Xm\|		NGS3TJZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTYEZ\|OUOgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiTFO1NEA:KDBwMzFOwG0v	NVvXcJl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
NCI60	NX62fY9ES3m2b4TvfIlkcXS7IHHzd4F6		NWDMeWExPiCmYYnz		M3nLbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUTZyIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvOzNizszNMi=>	NYThfYpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
SN12C	M3TlTmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlryOkBl[Xm\|		M{LSXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPOTKFIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvOzRizszNMi=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
MDA-MB-231	NXvtfpg{S3m2b4TvfIlkcXS7IHHzd4F6		NFLYV5o3KGSjeYO=		M3u0R2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNjDkZZl{KGK7IF3UWEBie3OjeTygWGdKKD1iMD6zOUDPxE1w	NGfG[pA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
ACHN	NU\mOVRrS3m2b4TvfIlkcXS7IHHzd4F6		MUG2JIRigXN?		MnnaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRWNJViClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBVT0liPTCwMlc{KM7:TT6=	NYLzWVhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
SN12C	NUXNN5lGS3m2b4TvfIlkcXS7IHHzd4F6		MWC2JIRigXN?		NFPZXm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUVjF{QzDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hOS53IN88UU4>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
UO31	NELJNZBEgXSxdH;4bYNqfHliYYPzZZk>		Mn7YOkBl[Xm\|		NGjLcFFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWVzNzIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFEvPTVizszNMi=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
Caki1	MVnDfZRwfG:6aXPpeJkh[XO\|YYm=		MX22JIRigXN?		NUnBSWs{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2GtaUGgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiVFfJJF0hOS56OTFOwG0v	M{TjO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
NCI60	NEn5cYVEgXSxdH;4bYNqfHliYYPzZZk>		MmPOOkBl[Xm\|		NYfVcG5NS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLNkCgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiTFO1NEA:KDNwNTFOwG0v	NV31T5dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
MDA-MB-231	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=		MmnEOkBl[Xm\|		NWTjNYp4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBNSzVyIE2gOE4xQCEQvF2u	NETudmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
MDA-MB-468	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=		NVX4Z2VjPiCmYYnz		M3TVe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZYZ1\XJiNjDkZZl{KGK7IF3UWEBie3OjeTygUGM2OCB;IESuNVQh\|ryPLh?=	M3jmZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
ACHN	M1zuNWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1\ZXFYh\GG7cx?=		NIDDNWdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCS0iQIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUA2NjN5IN88UU4>	M1zjTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
UACC257	NGC4WHREgXSxdH;4bYNqfHliYYPzZZk>		NH2x[m43KGSjeYO=		M1mxOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHVCS0N{NUegZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiTFO1NEA:KDVwNE[g{txONg>?	NF3TdpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
NCI-H322M	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		MWW2JIRigXN?		NEnUWW1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEOyNm0h[2WubIOgZYZ1\XJiNjDkZZl{KGK7IF3UWEBie3OjeTygUGM2OCB;IEmuNFIh\|ryPLh?=	MlL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
SF295	MXfDfZRwfG:6aXPpeJkh[XO\|YYm=		NV3iVWpvPiCmYYnz		NEC2OG5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ7NTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hOTBwMjFOwG0v	M3flWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
Caki1	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=		NV;ZWZRZPiCmYYnz		M4nDVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNic2lzIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUAzOC57IN88UU4>	NVvVR5hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
NCI-H23	MVLBcpRqfHWvb4KgZZN{[Xl?	MXyxMlYhfG9iMj60JI1oN2up	M4rsW5VxKHSxIEWg[IF6ew>?		NEH6PHdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGmvcHzhcpRm\CCrboTyZZBmemm2b37lZYxtgSCrbjDtc5V{\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpKGG2IEGuOkB1dyB{LkSgcYcwc2duIHnwJIFldWmwaYP0[ZJm\CCxbjDkZZkhOSC2bzC0JI1m[XO3cnXkJI9vKGSjeTC1JIJ6KGixbHzve{BncWKncjDhd5NigQ>?	NHGxPXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
NCI-H522	MnPQRY51cXS3bX;yJIF{e2G7	Ml3uNU43KHSxIEKuOEBu\y:tZx?=	NIL2PG52eCC2bzC1JIRigXN?		MY\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFUzOiClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
OVCAR5	MU\BcpRqfHWvb4KgZZN{[Xl?	MnfpNU43KHSxIEKuOEBu\y:tZx?=	NWPQUFl5fXBidH:gOUBl[Xm\|		M{DEVGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTPSClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	MnH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
SW620	M{T4fWFvfGm2dX3vdkBie3OjeR?=	M2LkOFEvPiC2bzCyMlQhdWdxa3e=	M4fqfJVxKHSxIEWg[IF6ew>?		MXfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{[yNEBk\WyuczDpcZBt[W62ZXSgbY51emGyZYLpeI9v\WGubImgbY4hdW:3c3WgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eY1weiClZXzsJIdzd3e2aDDheEAyNjZidH:gNk41KG2pL3vnMEBqeCCjZH3pcol{fGW{ZXSgc44h\GG7IEGgeI8hPCCvZXHzeZJm\CCxbjDkZZkhPSCkeTDoc4xtd3diZnni[ZIh[XO\|YYm=	M4nPZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
MDA-MB-435	NHX1[3JCdnSrdIXtc5Ih[XO\|YYm=	M4fGdFEvPiC2bzCyMlQhdWdxa3e=	MYL1dEB1dyB3IHThfZM>		MUfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuPDN3IHPlcIx{KGmvcHzhcpRm\CCrboTyZZBmemm2b37lZYxtgSCrbjDtc5V{\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpKGG2IEGuOkB1dyB{LkSgcYcwc2duIHnwJIFldWmwaYP0[ZJm\CCxbjDkZZkhOSC2bzC0JI1m[XO3cnXkJI9vKGSjeTC1JIJ6KGixbHzve{BncWKncjDhd5NigQ>?	NWmxO3ZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
COLO205	NY\WeWRESW62aYT1cY9zKGG\|c3H5	NYfGWIY5OS54IITvJFIvPCCvZz;r[y=>	MmTJeZAhfG9iNTDkZZl{		MUTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	NIfW[mU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
LOXIMVI	MUXBcpRqfHWvb4KgZZN{[Xl?	M3f6elEvPiC2bzCyMlQhdWdxa3e=	Mn7xeZAhfG9iNTDkZZl{		MmXkRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF;YTW1XUSClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
UACC62	NEXBeldCdnSrdIXtc5Ih[XO\|YYm=	NHXHWmoyNjZidH:gNk41KG2pL3vn	NIHtT4h2eCC2bzC1JIRigXN?		NWezUGJqSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gWWFESzZ{IHPlcIx{KGmvcHzhcpRm\CCrboTyZZBmemm2b37lZYxtgSCrbjDtc5V{\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpKGG2IEGuOkB1dyB{LkSgcYcwc2duIHnwJIFldWmwaYP0[ZJm\CCxbjDkZZkhOSC2bzC0JI1m[XO3cnXkJI9vKGSjeTC1JIJ6KGixbHzve{BncWKncjDhd5NigQ>?	NWPsUFdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
MDA-MB-231	NIntPI5CdnSrdIXtc5Ih[XO\|YYm=	Mk\BNU43KHSxIEKuOEBu\y:tZx?=	NF;3TFV2eCC2bzC1JIRigXN?		MnzTRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCrbYDsZY51\WRiaX70doFx\XKrdH;u[YFtdHliaX6gcY92e2ViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dX3vdkBk\WyuIHfyc5d1cCCjdDCxMlYhfG9iMj60JI1oN2upLDDpdEBi\G2rbnnzeIVz\WRib36g[IF6KDFidH:gOEBu\WG\|dYLl[EBwdiCmYYmgOUBjgSCqb3zsc5ch\mmkZYKgZZN{[Xl?	M4XkT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
SF295	M3LRdGFvfGm2dX3vdkBie3OjeR?=	MlqzNU43KHSxIEKuOEBu\y:tZx?=	MYL1dEB1dyB3IHThfZM>		MmfKRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yPVUh[2WubIOgbY1xdGGwdHXkJIlvfHKjcHXybZRwdmWjbHz5JIlvKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiY3XscEBoem:5dHigZZQhOS54IITvJFIvPCCvZz;r[{whcXBiYXTtbY5qe3SncnXkJI9vKGSjeTCxJJRwKDRibXXhd5Vz\WRib36g[IF6KDViYomgbI9tdG:5IH\pZoVzKGG\|c3H5	NF;Qfmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
U251	NGewRnNCdnSrdIXtc5Ih[XO\|YYm=	MYexMlYhfG9iMj60JI1oN2up	Mk\VeZAhfG9iNTDkZZl{		MX3BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXMkWxJINmdGy\|IHntdIxidnSnZDDpcpRz[XCncnn0c45m[WyueTDpckBud3W\|ZTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKGOnbHyg[5Jwf3SqIHH0JFEvPiC2bzCyMlQhdWdxa3esJIlxKGGmbXnubZN1\XKnZDDvckBl[XliMTD0c{A1KG2nYYP1doVlKG:wIHThfUA2KGK7IHjvcIxwfyCoaXLldkBie3OjeR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
OVRAC3	MUTBcpRqfHWvb4KgZZN{[Xl?	M3T3SlEvPiC2bzCyMlQhdWdxa3e=	MnjDeZAhfG9iNTDkZZl{		MlK0RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\SRWM{KGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
LLC	M1rKWmZ2dmO2aX;uJIF{e2G7				NIOzTY5KdmirYnn0bY9vKG:oIFjERWMudWWmaXH0[YQhUEmILUHhcJBp[SCjY4Tpeol1gSCrbjDtc5V{\SCOTFOgZ4VtdHNuIFnDOVAhRSB{IN88UU4>	M4TDblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C1OlEzLz5{MkOwOVYyOjxxYU6=
NCI-H522	NWPXd4ZZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NHK4cZdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWyNkBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJINwdG:{aX3leJJq[yCvZYToc4QtKEeLNUCgQUAxNjByMUig{txONg>?	NGrTVYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
LOXIMVI	NFzjSFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NGDUZlRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBNV1iLTW\JJINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODB{NTFOwG0v	MnT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
A549	M{K1bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NUSyeJhbT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOjZizszNMi=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
OVCAR5	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NEjwVG5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkWgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODJ6IN88UU4>	NH;sb3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
MKN74	NV3SeXNIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNT244PCClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCwN{DPxE1w	NFjDcYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
NCI-H460	Mn7QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NHPLenpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJINwdG:{aX3leJJq[yCvZYToc4QtKEeLNUCgQUAxNjByMzFOwG0v	M4O5VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
HCT116	NWHUS2NZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NHvMOlVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzMU[gZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODNzIN88UU4>	MkXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
HCC2998	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MV3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR2MzQTl6IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA{OSEQvF2u	MlP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
MKN1	M2XRNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NHnxSmlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOU05zIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA{OiEQvF2u	NI[1[2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
SKOV3	MknXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NILJclRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0:YMzDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzNizszNMi=>	NV3DT3Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
HT-29	MmG1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MkCzS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFM{KM7:TT6=	NX3J[HU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
KM12	NHjvUXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MWDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDLUVEzKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[2:ub4LpcYV1emmlIH3leIhw\CxiR1m1NEA:KDBwMECzOEDPxE1w	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
DMS114	MnTCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M{LF[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGROWzFzNDDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzZizszNMi=>	NFLjSpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
SF539	NGLoNJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NVHRTZNWT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z3M{mgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODN4IN88UU4>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
U251	MkPZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NUjWc4FyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzlizszNMi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
SF295	M1vpUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NF\wc3RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPCEQvF2u	MnS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
MCF7	M4D0emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MmToS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCwOFIh\|ryPLh?=	Mor4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
NCI-H23	M363PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NE\zboFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzJINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODB2NjFOwG0v	NGS0PI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
OVCAR3	M2n2W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MoLCS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU3ZESVJ\|IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA1PiEQvF2u	M1XyO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
MKN7	M1jsXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNT244KGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[2:ub4LpcYV1emmlIH3leIhw\CxiR1m1NEA:KDBwMEC0PUDPxE1w	M{fmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
SF268	MnriS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NF\QSHVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUTjJ4ODDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPDlizszNMi=>	MofuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
MDA-MB-231	MonZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M3TqbGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZpkhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNibXX0bI9lNCCJSUWwJF0hOC5yMEW1JO69VS5?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
OVCAR8	NFnuSVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MV;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPWmNCWjhiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFU2KM7:TT6=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
DMS273	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MVrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEUXMzPzNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFU5KM7:TT6=	M3\CRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
DU145	M2r1[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NYPaXYFrT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODZizszNMi=>	NFzFb2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
RXF631L	NXX3TJZVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NFv5UYFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBTYEZ4M{HMJINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODB4NjFOwG0v	MkTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
HBC4	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M2m3OWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhDSzRiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFY6KM7:TT6=	M1HWNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
SNB75	Mnj2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NWCwOooxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW06EN{WgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODd{IN88UU4>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
BSY1	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MkX3S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRnN[OSClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCwPFUh\|ryPLh?=	M{\MR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
NCI-H226	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MYDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ{NjDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxQDlizszNMi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
SNB78	MmXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NYDae4tsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW06EN{igZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODl4IN88UU4>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
HBC5	MoKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MV;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIRmM2KGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[2:ub4LpcYV1emmlIH3leIhw\CxiR1m1NEA:KDBwMEGzJO69VS5?	Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
MKN45	NITyfVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M1;NV2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1MVjR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFE1KM7:TT6=	NXPLVmZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
MKN28	NYfX[5BOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MkfkS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWtPOjhiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNVch\|ryPLh?=	M1\IT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
PC3	NXr4O4lPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NXLWUGtLT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN\|IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFE5KM7:TT6=	NXjmOJNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
ACHN	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NV;uOG5mT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSUOKTjDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAzKM7:TT6=	M3TKe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
OVCAR4	NFywOlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NXnBS3FvT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK0JINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODJizszNMi=>	Mn31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
St-4	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NX3R[3l7T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW3RvNDDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAzOiEQvF2u	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
HCT15	M2rxN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NGnLO4VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzNTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlQ2KM7:TT6=	M4DxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
CD4+ T	M4D3b2Z2dmO2aX;uJIF{e2G7		MWO3JIRigXN?		M3vDcXJm[WO2aY\heIlwdiCxZjDsZZRmdnRiSFnWNUBPVDRvMz3MeYMh\XiycnXzd4lwdiCrbjDoeY1idiCwYXn2[UBETDRtIGSgZ4VtdHNidILlZZRm\CB5IHThfZMheG:\|dD3pcoZm[3Srb36gcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IHz1cYlv\XOlZX7j[UBxdGG2ZTDy[YFl\XJiYX7hcJl{cXNuIFXDOVAhRSByLkCwN{DPxE1w	NVTnNnFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVUyODVpPkK0OFk2OTB3PD;hQi=>
NCI-H522	M4\uZmN6fG:2b4jpZ4l1gSCjc4PhfS=>				NHLGZXJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEWyNkBk\WyuczDifUBUWkJiYYPzZZktKEeLNUCgQUAxNjByMUig{txONg>?	M2m5b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
LOXIMVI	NVqyR2xGS3m2b4TvfIlkcXS7IHHzd4F6				Mmj3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG9ZUU2YSTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxOjVizszNMi=>	NYDyZYM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
A549	MVjDfZRwfG:6aXPpeJkh[XO\|YYm=				NXnteGFWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxOjZizszNMi=>	NHzN[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
OVCAR5	NXXTRZp5S3m2b4TvfIlkcXS7IHHzd4F6				MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFI5KM7:TT6=	MkDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
NCI-H460	NIW1dpNEgXSxdH;4bYNqfHliYYPzZZk>				NYC2eGZyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwJF0hOC5yMEOg{txONg>?	MknHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
MKN74	MlTOR5l1d3SxeHnjbZR6KGG\|c3H5				Ml[xR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWtPPzRiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFMh\|ryPLh?=	NVW2SFluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
HCC2998	MnHiR5l1d3SxeHnjbZR6KGG\|c3H5				MlrlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNEOjl7ODDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxOzFizszNMi=>	NIH0c\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
HCT116	NE\pT\|hEgXSxdH;4bYNqfHliYYPzZZk>				Ml;MR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA{OSEQvF2u	NEjMPXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
MKN1	NGj0TJJEgXSxdH;4bYNqfHliYYPzZZk>				MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNT24yKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMECzNkDPxE1w	M2Lr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
HT-29	NH7RUoREgXSxdH;4bYNqfHliYYPzZZk>				MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|Mh\|ryPLh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SKOV3	M3zUVGN6fG:2b4jpZ4l1gSCjc4PhfS=>				MkPBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFM{KM7:TT6=	NVrQXW5bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
KM12	M1T4NGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NXjreJpIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU01zMjDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxOzRizszNMi=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SF539	NGnI[WREgXSxdH;4bYNqfHliYYPzZZk>				MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlU{QSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|Yh\|ryPLh?=	MnXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
293T	MXzGeY5kfGmxbjDhd5NigQ>?		M3noelMxKG2rboO=		NUeySoxbUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNUBmgHC{ZYPz[YQhcW5iaIXtZY4hOjl\|VDDj[YxteyC3c3nu[{BC[y2NR1zHT{hC[ylvTVPBJIF{KHO3YoP0doF1\SCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMECzOkDPxE1w	M2\CPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
DMS114	Mn7JR5l1d3SxeHnjbZR6KGG\|c3H5				NGjJZ2VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFVVNzMUSgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODN4IN88UU4>	MnPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
U251	Ml6zR5l1d3SxeHnjbZR6KGG\|c3H5				MlzsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVI2OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|kh\|ryPLh?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SF295	MnnYR5l1d3SxeHnjbZR6KGG\|c3H5				MkH6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzQTViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFQh\|ryPLh?=	NUG5WnNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
MCF7	MojMR5l1d3SxeHnjbZR6KGG\|c3H5				MknkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwOFIh\|ryPLh?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
OVCAR3	NFrtTJZEgXSxdH;4bYNqfHliYYPzZZk>				MoHFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA1PiEQvF2u	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
NCI-H23	NWjLOIpjS3m2b4TvfIlkcXS7IHHzd4F6				MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA1PiEQvF2u	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SF268	NUTNW2VrS3m2b4TvfIlkcXS7IHHzd4F6				M3q4XWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNHOjZ6IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA1QSEQvF2u	NF2y[G09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
MKN7	MnrXR5l1d3SxeHnjbZR6KGG\|c3H5				MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNT244KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEC0PUDPxE1w	NIPkSFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
OVCAR8	NIPvS4FEgXSxdH;4bYNqfHliYYPzZZk>				Ml[1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA2PSEQvF2u	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
MDA-MB-231	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=				NF;ze5NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEC1OUDPxE1w	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
DMS273	NV;HPFZ7S3m2b4TvfIlkcXS7IHHzd4F6				M4nTUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGROWzJ5MzDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxPThizszNMi=>	NGjMNFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
DU145	NYeyXpVwS3m2b4TvfIlkcXS7IHHzd4F6				MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwOkDPxE1w	NIqzeWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
RXF631L	M3niUmN6fG:2b4jpZ4l1gSCjc4PhfS=>				NUSxfI5KS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWliINkOxUEBk\WyuczDifUBUWkJiYYPzZZktKEeLNUCgQUAxNjByNk[g{txONg>?	NIS0OWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
HBC4	NIrTNJdEgXSxdH;4bYNqfHliYYPzZZk>				M{jPXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhDSzRiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFY6KM7:TT6=	MmnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
SNB75	NXfFeGNNS3m2b4TvfIlkcXS7IHHzd4F6				NH\TXG5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUVkJ5NTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxPzJizszNMi=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
BSY1	M4n6WWN6fG:2b4jpZ4l1gSCjc4PhfS=>				MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCV3kyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEC4OUDPxE1w	NHLkPGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
NCI-H226	M3HIc2N6fG:2b4jpZ4l1gSCjc4PhfS=>				M1TXO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMkK2JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB6OTFOwG0v	NGK4eVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
SNB78	NEDKfplEgXSxdH;4bYNqfHliYYPzZZk>				Mk\LR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV25DPzhiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFk3KM7:TT6=	NGjzTI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
HBC5	M{T0TGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NXvqbHJKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEKFNTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAyOyEQvF2u	M1;3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
MKN45	NIHiNlJEgXSxdH;4bYNqfHliYYPzZZk>				NYfQSZF2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUuQNEWgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xOTRizszNMi=>	NWLoUXozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
MKN28	MYnDfZRwfG:6aXPpeJkh[XO\|YYm=				NHzSO3BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOU05{ODDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAyPyEQvF2u	MlPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
PC3	MnfXR5l1d3SxeHnjbZR6KGG\|c3H5				M2jHcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCxPEDPxE1w	M3zrdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
ACHN	NXLCTpM4S3m2b4TvfIlkcXS7IHHzd4F6				MojRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRWNJViClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCyJO69VS5?	NGSwc289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
OVCAR4	NFPoZmZEgXSxdH;4bYNqfHliYYPzZZk>				M3qwNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUNDDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAzKM7:TT6=	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
St-4	NFrjXY5EgXSxdH;4bYNqfHliYYPzZZk>				MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTeE01KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEKyJO69VS5?	M2[1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
293T	MofwSpVv[3Srb36gZZN{[Xl?		M4j4UVMxKG2rboO=		MVrJcohq[mm2aX;uJI9nKG2xdYPlJGhFSUN4IHX4dJJme3OnZDDpckBpfW2jbjCyPVNVKGOnbHzzJJV{cW6pIFHjMWtIVEeNKFHjLU1OS0FiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4{QSEQvF2u	NGTyPYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
HCT15	MmHVR5l1d3SxeHnjbZR6KGG\|c3H5				MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkS1JO69VS5?	MnfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
mink Mv1Lu	M1GwTWZ2dmO2aX;uJIF{e2G7		NI[3UnkzPCCqcoO=		MoP6TY5kemWjc3WgbY4hcHWvYX6ge4lt\CC2eYDlJJAzOSCycn;0[YlvKGW6cILld5Nqd25iaX6gcYlvcyCPdkHMeUBk\WyuczDh[pRmeiB{NDDodpMh[nlicEKxJJBzd22xdHXyJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDBwMTDtUUBlcXSqaX;0bJJmcXSxbDygSWMyODByIE2gNE4xOTV5IN88UU4>	NV;HZ4pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc2PzhpPkK0PVk4PTd6PD;hQi=>
HCT116	M4DONGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXe0PEBpenN?		MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB2ODDodpMhcW5icILld4Vv[2Vib3[gSHRVKGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA{KM7:TT6=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2N{[xNkc,OjVzNEe2NVI9N2F-
MOLT4	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWG3NkBpenN?		MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDHTVUxKD1iMD6wNFIxPiEQvF2u	Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|M{GzN\|QoRjJ4M{OxN\|M1RC:jPh?=
DU145	M{DadGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mn\qO\|IhcHK\|		M{m4cGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGdKPTBiPTCwMlAxOjV3IN88UU4>	M3\5TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{OxN\|M1Lz5{NkOzNVM{PDxxYU6=
U937	Ml\0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NELNOXI4OiCqcoO=		MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV7M{egZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFfJOVAhRSByLkCwN\|QyKM7:TT6=	MmrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|M{GzN\|QoRjJ4M{OxN\|M1RC:jPh?=
HLF	M3fpOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MnvyO\|IhcHK\|		MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiORjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiR1m1NEA:KDBwMEC0PFkh\|ryPLh?=	NH7C[4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzNVM{PCd-Mk[zN\|E{OzR:L3G+
WI38	NXzJTm9nSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXi3NkBpenN?		MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFeLM{igZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFfJOVAhRSByLkCwOVM6KM7:TT6=	NUfKbWg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN\|E{OzRpPkK2N\|MyOzN2PD;hQi=>
U937	MnXGSpVv[3Srb36gZZN{[Xl?		NE[4PYozPCCqcoO=		M{XCbGlvcGmkaYTpc44hd2ZiSFTBR\|YhcW5iaIXtZY4hXTl\|NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[WyyaHGteJVjcWyrbjDhZ4V1gWyjdHnvckBifCB3IH7NJJRwKDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NV2wbY4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN\|E{OzRpPkK2N\|MyOzN2PD;hQi=>
HCT116	NV;FSI1CSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWf4cY0{PzJiaILz		MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSClb4XseIVzKGOxdX70[ZIhdWW2aH;kMEBKSzVyIE2gNE4xOjhizszNMi=>	M{joUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEixOlU6Lz5{NkS4NVY2QTxxYU6=
IGROV1/Pt1	NWHUdmZlSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmjxO\|IhcHK\|		NVzMS3ZmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDJS3JQXjFxUISxJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KGOxdXz0[ZIh[2:3boTldkBu\XSqb3SsJGlEPTBiPTCwMlA5KM7:TT6=	NYTsXJNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0PFE3PTlpPkK2OFgyPjV7PD;hQi=>
IGROV1	NULn[otoSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWi3NkBpenN?		NWXQbnpnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDJS3JQXjFiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgZ492dHSncjDjc5VvfGW{IH3leIhw\CxiSVO1NEA:KDBwMkKg{txONg>?	NG\GblU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4NVY2QSd-Mk[0PFE3PTl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p21 / Cyclin D1; PubMed: 19682393 J Mol Signal NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments. AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); PubMed: 26473529 Blood Cancer J Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot. HDAC3 / HDAC4 / HDAC6 / HDAC2; PubMed: 26473529 Blood Cancer J Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot. γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; PubMed: 26473529 Blood Cancer J Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed. Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; PubMed: 27444036 Gynecol Oncol Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. pAKT(S473) / pAKT(T308) / AKT; PubMed: 25492515 Cancer Sci Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228.	19682393 26473529 27444036 25492515
Growth inhibition assay	Cell viability; PubMed: 27444036 Gynecol Oncol Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments.	27444036
Immunofluorescence	SS18/TLE1; PubMed: 27120803 Oncotarget A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells. Cleaved caspase-3; PubMed: 22531354 J Ovarian Res TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).	27120803 22531354

In vivo

Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. ^[4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse HDAC-inhibitory activity: For the enzyme assay, 10 μL of [³H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [³H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research: ^[3]	- Collapse Cell lines: HL60, Jurkat, A549, and MCF-7 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: Male scid mice inoculated i.p. with U-937 cells Dosages: ~1 mg/kg once or twice a week Administration: Treated i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	10 mg/mL (18.49 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5%Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	540.7
Formula	C₂₄H₃₆N₄O₆S₂
CAS No.	128517-07-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	FR 901228, NSC 630176
Smiles	CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03770000	Active not recruiting	Drug: Tenalisib\|Drug: Romidepsin	T Cell Lymphoma	Rhizen Pharmaceuticals SA	March 12 2019	Phase 1\|Phase 2
NCT02616965	Recruiting	Drug: Romidepsin\|Drug: Brentuximab vedotin	Cutaneous T-cell Lymphoma (CTCL)	Fox Chase Cancer Center\|Seagen Inc.\|Celgene Corporation	February 22 2017	Phase 1
NCT02616874	Completed	Drug: MVA.HIVconsv vaccine\|Drug: Romidepsin	HIV	IrsiCaixa\|Germans Trias i Pujol Hospital\|Fundación FLS de Lucha Contra el Sida las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia\|Hospital Clinic of Barcelona\|Hospital de Sant Pau\|HIVACAT\|University of Oxford\|BCN Checkpoint	February 2016	Phase 1
NCT03141203	Active not recruiting	Drug: Romidepsin\|Drug: Carfilzomib	Peripheral T Cell Lymphoma	University of Birmingham\|Bloodwise\|Celgene\|Amgen	July 13 2015	Phase 1\|Phase 2
NCT02296398	Completed	Drug: Romidepsin	Cutaneous T-cell Lymphoma	Northwestern University	January 2015	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Pan HDAC Inhibitor

Panobinostat (LBH589) : Pan-HDAC inhibitor, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Romidepsin (FK228, Depsipeptide)